Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5049562 | 0.89 | SMN1; SMN2 (0.46) | MAPTL3MBTL1SMN1; SMN2PTGS2LMNA | |
| SCHEMBL4267097 | 0.85 | L3MBTL1 (0.44) | MAPTL3MBTL1SMN1; SMN2GAALMNA | |
| SCHEMBL809993 | 0.83 | PTGS2 (0.50) | MAPTL3MBTL1SMN1; SMN2PTGS2GAA | |
| SCHEMBL23605758 | 0.77 | MAPT (0.69) | MAPTL3MBTL1SMN1; SMN2GAALMNA | |
| SCHEMBL2116437 | 0.77 | PTGS2 (0.66) | MAPTL3MBTL1SMN1; SMN2PTGS2GAA | |
| SCHEMBL10771802 | 0.76 | MAPT (0.62) | MAPTL3MBTL1SMN1; SMN2GAALMNA | |
| SCHEMBL9168331 | 0.76 | MAPT (0.62) | MAPTL3MBTL1SMN1; SMN2GAALMNA | |
| SCHEMBL4264046 | 0.74 | PTGS2 (0.58) | MAPTL3MBTL1SMN1; SMN2PTGS2GAA | |
| SCHEMBL13935133 | 0.74 | PTGS2 (0.58) | MAPTL3MBTL1SMN1; SMN2PTGS2GAA | |
| SCHEMBL8284596 | 0.74 | RAB9A (0.60) | MAPTL3MBTL1SMN1; SMN2PTGS2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8802892-B2 | Functionalized phenolic compounds and polymers therefrom | BEZWADA BIOMEDICAL, LLC (US) | 2014-08-12 | — | — | US | disclosed |
| US-8802892-B2 | Functionalized phenolic compounds and polymers therefrom | BEZWADA BIOMEDICAL, LLC (US) | 2014-08-12 | — | — | US | disclosed |
| US-8802892-B2 | Functionalized phenolic compounds and polymers therefrom | BEZWADA BIOMEDICAL, LLC (US) | 2014-08-12 | — | — | US | disclosed |
| US-20130281652-A1 | FUNCTIONALIZED PHENOLIC COMPOUNDS AND POLYMERS THEREFROM | BEZWADA BIOMEDICAL, LLC | 2013-10-24 | — | — | US | disclosed |
| US-20130281652-A1 | FUNCTIONALIZED PHENOLIC COMPOUNDS AND POLYMERS THEREFROM | BEZWADA BIOMEDICAL, LLC | 2013-10-24 | — | — | US | disclosed |
| US-20130281652-A1 | FUNCTIONALIZED PHENOLIC COMPOUNDS AND POLYMERS THEREFROM | BEZWADA BIOMEDICAL, LLC | 2013-10-24 | — | — | US | disclosed |
| US-8318973-B2 | Functionalized sinapic acid and methyl sinapate | BEZWADA BIOMEDICAL, LLC (US) | 2012-11-27 | — | — | US | disclosed |
| US-8318973-B2 | Functionalized sinapic acid and methyl sinapate | BEZWADA BIOMEDICAL, LLC (US) | 2012-11-27 | — | — | US | disclosed |
| US-8318973-B2 | Functionalized sinapic acid and methyl sinapate | BEZWADA BIOMEDICAL, LLC (US) | 2012-11-27 | — | — | US | disclosed |
| US-20090170927-A1 | FUNCTIONALIZED PHENOLIC COMPOUNDS AND POLYMERS THEREFROM | BEZWADA BIOMEDICAL, LLC (US) | 2009-07-02 | — | — | US | disclosed |
| US-20090170927-A1 | FUNCTIONALIZED PHENOLIC COMPOUNDS AND POLYMERS THEREFROM | BEZWADA BIOMEDICAL, LLC (US) | 2009-07-02 | — | — | US | disclosed |
| US-20090170927-A1 | FUNCTIONALIZED PHENOLIC COMPOUNDS AND POLYMERS THEREFROM | BEZWADA BIOMEDICAL, LLC (US) | 2009-07-02 | — | — | US | disclosed |
| WO-2007053794-A2 | FUNCTIONALIZED PHENOLIC COMPOUNDS AND ABSORBABLE THEREFROM | BEZWADA BIOMEDICAL LLC (US) | 2007-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170927-A1 | FUNCTIONALIZED PHENOLIC COMPOUNDS AND POLYMERS THEREFROM | COMT, AOX1, UGT1A6 | MAPT 2351/4885L3MBTL1 4710/4885SMN1; SMN2 4737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.